Search Results - down

1 Results

Sort By:

Discovery of Proteasome Inhibitors to Target PMP22 Gene Expression for the Treatment of Charcot-Marie-Tooth Disease Type 1A

This technology includes the use of proteasome inhibitors, such as Bortezomib, for the treatment of the most prevalent form of Charcot-Marie-Tooth disease type 1A (CMT1A). Duplication of the peripheral myelin protein 22 (PMP22) gene, normally involved in myelination of the peripheral nervous system, is the causative agent in most forms of CMT1A. A drug...

Published: 7/25/2024 | Inventor(s): Sung-Wook Jang, John Svaren, James Inglese

Keywords(s): Discovery, DOWN, Expression, Gene, inhibition, Listed LPM Tong as of 4/15/2015, MEANS, Pmp22, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Proteasome, REGULATE, VEXXXX, WKXXXX, XEXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Neurology